CCA
BMY icon

Criterion Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Criterion Capital Advisors’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-68
Closed -$3.69K – 350
2024
Q1 		$3.69K Buy
+68
New +$3.46K ﹤0.01% 298

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Criterion Capital Advisors's BMY Position: Q2 2024 in Review

Criterion Capital Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 68 shares — an estimated $3.69K sold.

Criterion Capital Advisors first reported a position in BMY in Q1 2024 and held it in 1 quarter. The position peaked at $3.69K in Q1 2024. 2,154 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

  • Criterion Capital Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
  • Criterion Capital Advisors sold 68 Bristol-Myers Squibb shares in Q2 2024, an estimated $3.69K.
  • Criterion Capital Advisors first reported a position in Bristol-Myers Squibb in Q1 2024 and held it in 1 quarter.
  • Criterion Capital Advisors's Bristol-Myers Squibb position peaked at $3.69K in Q1 2024.
  • 2,154 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Criterion Capital Advisors's 13F filing for Q2 2024, filed 31 Jul 2024.